57
Participants
Start Date
September 30, 2008
Primary Completion Date
May 31, 2011
Study Completion Date
September 30, 2012
Pazopanib
800 mg of pazopanib orally each day continuously
Virginia Cancer Institute, Richmond
South Carolina Oncology Associates, PA, Columbia
Northeast Georgia Medical Center, Gainesville
Medical Oncology Associates of Augusta, Augusta
Florida Hospital Cancer Institute, Orlando
Gulfcoast Oncology Associates, St. Petersburg
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Baptist Hospital East, Louisville
Oncology Hematology Care, Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
St. Louis Cancer Care, Chesterfield
University of Nebraska Medical Center, Omaha
San Francisco Oncology Associates, San Francisco
Central Maine Medical Center, Lewiston
Collaborators (1)
GlaxoSmithKline
INDUSTRY
SCRI Development Innovations, LLC
OTHER